Shots:
- Flare Therapeutics has dosed its first patient with FX-909 in P-Ib trial for the treatment of locally-advanced or metastatic urothelial cancer
- The P-Ib trial will assess FX-909 (30 & 50mg; QD) in 40 pts, incl. a biomarker-defined population, building on clinical PoC achieved in P-Ia, with P-Ia data to be presented in 2025. Efficacy data at the recommended P-II dose in a biomarker-defined population is expected in Q1’26
- Trial will use a validated immunohistochemistry (IHC)-based test to prospectively identify pts expressing the lineage-defining transcription factor driving tumor initiation & progression
Ref: Flare Therapeutics| Image: Flare Therapeutics| Press Release
Related News:- Ethris Reports First Patient Dosing in P-IIa Trial of ETH47 for Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
